DEA has announced that the same company that makes fentanyl, a pharmaceutical drug often deemed more dangerous than heroin, will be coming to the market soon with a synthetic form of cannabis.
The drug will be called Syndros, and is a synthetic form of THC. However, THC will remain a schedule 1 substance and Syndros will be classified as a Schedule 2 substance. Meaning it can be prescribed legally in all 50 states.
With organic cannabis remaining a schedule 1 substance, the DEA still considers it to have “no currently accepted medical use” and “a high potential for abuse”. It’s schedule one status also lumps it in with heroin, which is also schedule one.
The FDA has also approved Syndros, so it will be hitting the market soon. It is made by a company called Insys Therapeutics, an Arizona-based pharmaceutical company. This company hasn’t had the cleanest history. A few top executives have been arrested and charged for bribing doctors and defrauding insurance companies. The company itself has had numerous lawsuits for allegedly triggering America’s opioid crisis. Now they are working to take over cannabis.